FXIII deficiency is a very rare coagulation disorder that can affect equally males and females with an estimated incidence of 1 in 2 million persons worldwide. Due to this rarity, there are only few clinical and pharmacokinetic (PK) data deriving from the real-world.
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison
Pasca, Samantha
Writing – Review & Editing
;
2022
Abstract
FXIII deficiency is a very rare coagulation disorder that can affect equally males and females with an estimated incidence of 1 in 2 million persons worldwide. Due to this rarity, there are only few clinical and pharmacokinetic (PK) data deriving from the real-world.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Pasca, 2022 - JTT.pdf
accesso aperto
Tipologia:
Postprint (accepted version)
Licenza:
Accesso libero
Dimensione
375.33 kB
Formato
Adobe PDF
|
375.33 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
